Literature DB >> 10049272

Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.

S A Zelenitsky1, B Booker, N Laing, J A Karlowsky, D J Hoban, G G Zhanel.   

Abstract

The pharmacodynamics of an investigational glycopeptide, LY333328 (LY), alone and in combination with gentamicin, against one vancomycin-susceptible and two vancomycin-resistant Enterococcus faecium strains were studied with a multiple-dose, in vitro pharmacodynamic model (PDM). Dose-range data for the PDM studies were obtained from static time-kill curve studies. In PDM experiments conducted over 48 h, peak LY concentrations of 0.1x and 1x the MIC every 24 h and peak gentamicin concentrations of 18 micrograms/ml every 24 h (Gq24 h) and 6 micrograms/ml every 8 h (Gq8 h) were studied alone and in the four possible LY-gentamicin combinations. Compared to either antibiotic alone, LY-gentamicin combination regimens produced significantly higher apparent killing rates (KRs) calculated during the initial 2 h postdosing. The mean KRs for LY or gentamicin alone versus those for the LY-gentamicin combination regimens were 0.35 +/- 0.55 log10 CFU/ml/h (95% confidence interval [CI95%], 0 to 0.70) and 1.46 +/- 0.71 log10 CFU/ml/h (CI95%, 1.01 to 1.91), respectively (P < 0.0001). Bacterial killing at 48 h (BK48), which was calculated by subtracting the bacterial counts at 48 h from the initial inoculum, with a negative value indicating net growth, was also significantly greater. The mean BK48S were -0.69 +/- 0.44 log10 CFU/ml (CI95%, -0.41 to -0.97) and 3.72 +/- 2.28 log10 CFU/ml (CI95%, 2.28 to 5.17) for LY or gentamicin alone versus LY-gentamicin combination regimens, respectively (P < 0.0001). None of the 12 regimens with LY or gentamicin alone but 75% (9 of 12) of the LY-gentamicin combination regimens were bactericidal. Eighty-three percent (10 of 12) of the LY-gentamicin combination regimens also demonstrated synergy. No significant differences between the pharmacodynamics of LY-gentamicin combination regimens containing Gq24 h versus those containing Gq8h were detected.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10049272      PMCID: PMC89165     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Interactions of antimicrobial combinations in vitro: the relativity of synergism.

Authors:  J Blaser
Journal:  Scand J Infect Dis Suppl       Date:  1990

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

3.  In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.

Authors:  R S Schwalbe; A C McIntosh; S Qaiyumi; J A Johnson; R J Johnson; K M Furness; W J Holloway; L Steele-Moore
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

Review 4.  Management of infections due to resistant enterococci: a review of therapeutic options.

Authors:  D Landman; J M Quale
Journal:  J Antimicrob Chemother       Date:  1997-08       Impact factor: 5.790

5.  Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; M J Zweifel; S C Wilkie; M J Rodriguez; R C Thompson; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

6.  In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

Authors:  J Blaser
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

7.  Activities of the semisynthetic glycopeptide LY191145 against vancomycin-resistant enterococci and other gram-positive bacteria.

Authors:  T I Nicas; D L Mullen; J E Flokowitsch; D A Preston; N J Snyder; R E Stratford; R D Cooper
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

Review 8.  Bactericidal testing.

Authors:  C W Stratton
Journal:  Infect Dis Clin North Am       Date:  1993-06       Impact factor: 5.982

9.  In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.

Authors:  R N Jones; M S Barrett; M E Erwin
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

10.  Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection.

Authors:  M B Edmond; J F Ober; D L Weinbaum; M A Pfaller; T Hwang; M D Sanford; R P Wenzel
Journal:  Clin Infect Dis       Date:  1995-05       Impact factor: 9.079

View more
  9 in total

1.  Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis.

Authors:  Kavindra V Singh; Truc T Tran; Esteban C Nannini; Vincent H Tam; Cesar A Arias; Barbara E Murray
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

2.  Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci.

Authors:  M Arthur; F Depardieu; P Reynolds; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

3.  Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection.

Authors:  Carole J Boylan; Kristina Campanale; Philip W Iversen; Diane L Phillips; Michael L Zeckel; Thomas R Parr
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.

Authors:  A Lefort; A Saleh-Mghir; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 5.  New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

Authors:  Truc T Tran; Sara Gomez Villegas; Samuel L Aitken; Susan M Butler-Wu; Alex Soriano; Brian J Werth; Jose M Munita
Journal:  Antimicrob Agents Chemother       Date:  2022-04-27       Impact factor: 5.938

Review 6.  Glycopeptide antibiotics: from conventional molecules to new derivatives.

Authors:  Françoise Van Bambeke; Yves Van Laethem; Patrice Courvalin; Paul M Tulkens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing.

Authors:  Francis F Arhin; Ingrid Sarmiento; Adam Belley; Geoffrey A McKay; Deborah C Draghi; Parveen Grover; Daniel F Sahm; Thomas R Parr; Gregory Moeck
Journal:  Antimicrob Agents Chemother       Date:  2008-02-25       Impact factor: 5.191

Review 8.  Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.

Authors:  Françoise Van Bambeke
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

9.  Oritavancin diphosphate.

Authors:  Dennis J Cada; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.